Folic Acid

Written by: Dr Jeremy Steinberg – created: 6 May 2025; last modified: 6 May 2025

This page is probably complete!

It is awaiting peer review

Folate (Vitamin B9) is a B vitamin fundamental to numerous physiological processes, including the synthesis of nucleic acids and neurotransmitters essential for brain function. Its importance extends significantly into mental health, particularly concerning major depressive disorder. The connection between folate and psychiatric illness first emerged in the 1960s, when studies revealed folate deficiencies in a notable portion of psychiatric inpatients. This article reviews the historical context, underlying mechanisms, clinical evidence for different folate forms and related compounds like S-adenosylmethionine (SAMe), the role of genetic testing, and practical considerations for using folate supplementation in the management of depression. See also article on Nutritional Peripheral Neuropathies.

Folate Deficiency and its Association with Psychiatric Conditions

Following the development of clinical folate assays in the 1960s, low folate levels were correlated not only with conditions like anemia, neuropathy, neural tube defects, and dementia but also with psychiatric illness. Studies found low folate levels in approximately 25% of hospitalized psychiatric patients, particularly those with psychosis and depression. Notably, folate deficiency was frequently identified in individuals non-responsive to standard antidepressants, and supplementation often improved clinical outcomes.

Genetic factors contribute significantly to this association. Variations in the Methylenetetrahydrofolate Reductase (MTHFR) gene, which encodes a key enzyme in folate activation, are linked to depression. The common polymorphisms c.677C>T and c.1298A>C reduce the enzyme's efficiency. Possessing these variants increases the risk of depression by approximately 40% and these variants are more prevalent in depressed populations (~60%) compared to the general population (30-40%), especially among individuals of Hispanic or Mediterranean descent.

Two primary mechanisms link folate status to depression. Firstly, active folate (L-methylfolate) serves as an essential cofactor in the synthesis pathway of key monoamine neurotransmitters, including serotonin, dopamine, and norepinephrine. Impaired folate metabolism can therefore limit the production of these neurotransmitters implicated in mood regulation. Secondly, folate is vital for the metabolic conversion of homocysteine to methionine. Consequently, low folate levels or impaired MTHFR function can lead to elevated homocysteine, which is not only a risk factor for vascular disease but is also independently associated with depression and cognitive dysfunction.

The common MTHFR c.677C>T gene variant has also been linked to an increased risk of Diabetic Peripheral Neuropathy, likely due to its inhibitory effect on folic acid metabolic pathways.

Forms of Folate, Related Compounds, and Mechanisms

Several compounds related to folate metabolism are relevant to depression treatment. Folic acid is a synthetic, oxidized form commonly used in fortification and supplements, requiring multiple enzymatic steps for conversion to its active form. Folinic acid is a reduced form, metabolically closer to the active state, but still requiring enzymatic conversion. The biologically active form is L-methylfolate, which readily crosses the blood-brain barrier and directly participates in neurotransmitter synthesis and homocysteine methylation. The conversion of folic acid and folinic acid to L-methylfolate is significantly dependent on the MTHFR enzyme. While MTHFR polymorphisms reduce conversion efficiency, the enzymatic block is not absolute; theoretically, high doses of folic acid might overcome this limitation, though this specific strategy lacks dedicated study. Another relevant compound is S-adenosylmethionine (SAMe), a molecule produced downstream from L-methylfolate in the one-carbon cycle. SAMe acts as a primary methyl group donor, influencing monoamine metabolism and contributing to the reduction of homocysteine.

Folate Supplementation Evidence

The clinical evidence supporting the use of these compounds in depression varies significantly. For folic acid, the evidence is inconsistent. Despite some early positive signals, a large randomized controlled trial published in 2014 found high-dose folic acid (5 mg/day) ineffective as an adjunct treatment for depression. Evidence for folinic acid is sparse and largely inconclusive, stemming mainly from uncontrolled trials.

L-methylfolate possesses the most robust evidence base among the folate-related compounds. Nine controlled trials involving over 6,000 patients support its use as an augmentation strategy for standard antidepressants. Regarding efficacy, meta-analyses indicate an effect size (Cohen's d) of approximately 0.4 for augmentation, which is comparable to established strategies like lithium or atypical antipsychotics. The 15 mg/day dose appears more effective than 7.5 mg/day. Concerning MTHFR status, while trials did not specifically stratify outcomes by genotype to definitively prove it predicts response, related evidence suggests a significant impact. For instance, a trial of Enlyte (a medical food containing 7mg L-methylfolate plus other B vitamins and nutrients) demonstrated a large effect size (d=0.9) when used as monotherapy in depressed patients with confirmed MTHFR polymorphisms. This suggests L-methylfolate may be particularly effective in this subgroup, potentially achieving effect sizes substantially larger than standard augmentation agents.

There is one double-blind, randomized controlled trial alongside several open-label and retrospective studies that support the use of L-methylfolate (often as L-methylfolate calcium) in managing diabetic peripheral neuropathy (DPN).

For S-adenosylmethionine (SAMe), previously considered a promising natural antidepressant, recent analyses temper this view. Although SAMe functions similarly to L-methylfolate metabolically, much of the positive data originated from active-comparator trials, which are susceptible to high placebo effects that can mask true differences between treatments. A recent meta-analysis prioritizing placebo-controlled trials found SAMe no better than placebo overall for depression. Furthermore, issues with the molecule's instability, requiring specific blister packaging and enteric coating to maintain potency, may contribute to inconsistent clinical results. While definitive conclusions remain elusive due to numerous small studies, the current evidence supporting SAMe in depression appears less compelling than that for L-methylfolate.

It has also been studied for potentially reducing antidepressant-induced sexual dysfunction. Evidence supporting its use in liver disease, Parkinson's disease, dementia, and HIV is less robust.

A 1987 Italian RCT found SAMe at 1200mg daily was similar in effect to naproxen 750mg for osteoarthritis, with superior tolerability. A meta-analysis from 2002 concluded that SAMe was comparable to NSAIDs for improving pain and function in patients with osteoarthritis. A 2009 Cochrane review acknowledged a small potential benefit for pain (moderate quality) and function (low quality) but expressed greater uncertainty due to the methodological limitations of the trials and advised against routine use based on the evidence at that time.

For fibromyalgia, the evidence supporting SAMe is less consistent. An older double-blind clinical trial involving 44 patients reported that 800 mg of oral SAMe daily for six weeks led to improvements in clinical disease activity, pain, fatigue, morning stiffness, and mood compared to placebo. Nevertheless, comprehensive systematic reviews of fibromyalgia therapies often find that the evidence for many interventions, including various pharmacological agents, is limited or associated with only small effect sizes.

The inherent instability of the SAMe molecule, which necessitates specific blister packaging and enteric coating to maintain potency, may also contribute to the variability observed in clinical trial outcomes across different conditions if product quality and bioavailability are not rigorously controlled.

Clinical Considerations

Several clinical factors guide the use of these agents. Based on current evidence, L-methylfolate (15 mg/day) is the preferred folate-related intervention for augmenting antidepressant treatment. This preference is due to its robust efficacy data, favorable pharmacokinetics (including its ability to cross the blood-brain barrier), and excellent safety profile. The availability of generic forms has also made it cost-effective (approximately $0.25 USD/day). SAMe may be considered a secondary option or reserved for patients with specific comorbidities like osteoarthritis or fibromyalgia.

Regarding MTHFR testing, while readily available (e.g., through pharmacogenomic panels like Genesight testing for c.677C>T), its routine use to specifically guide L-methylfolate therapy is questionable. Clinical trials have not directly correlated MTHFR status with L-methylfolate response outcomes. Furthermore, several clinical factors can strongly predict potential benefit without the added cost of genetic testing. However, if MTHFR results are already available from previous testing, they can contribute valuable information to the overall clinical picture.

Certain clinical characteristics suggest a higher likelihood of response to L-methylfolate, often guiding treatment decisions more effectively than genetic testing alone. These clinical predictors include:

• Obesity (BMI > 30)
• Evidence of inflammation (high-sensitivity C-Reactive Protein > 3 mg/L), as inflammation increases folate consumption and decreases absorption.
• Presence of risk factors for low serum folate, such as renal failure, gastrointestinal diseases affecting absorption, alcohol use disorder (particularly liquor), smoking, eating disorders, or poor nutrition.
• Concurrent use of medications known to interfere with folate metabolism, including lamotrigine, valproate, carbamazepine, phenytoin, fluoxetine, oral contraceptives, methotrexate, metformin, sulfasalazine, warfarin, or triamterene.

For practical application, given L-methylfolate's safety and low cost, an empirical trial of 15 mg/day is often a reasonable approach for antidepressant augmentation. Clinicians can assess efficacy for individual patients by obtaining baseline and follow-up depression severity ratings (e.g., using the Patient Health Questionnaire-9 [PHQ-9] at baseline and after approximately one month). If effective, long-term supplementation may be warranted. In terms of interactions, while high-dose folic acid may interfere with lamotrigine efficacy, there is no evidence suggesting L-methylfolate does so. A small randomized controlled trial found that adding L-methylfolate 15 mg daily to lamotrigine improved mood in patients with bipolar depression without inducing mania. SAMe is generally considered safe to use with standard antidepressants, although theoretical caution regarding potential serotonin syndrome exists when combined with Monoamine Oxidase Inhibitors (MAOIs).

If SAMe is used, the typical dosing strategy involves starting at 400 mg once daily and titrating upwards by 200-400 mg every 3-7 days, aiming for a target dose of 800-1600 mg per day. It should be taken on an empty stomach for optimal absorption. Ensure patients use products manufactured with appropriate blister packaging and enteric coating to maintain stability. The cost is typically higher than L-methylfolate, around $40-80 USD per month.

Context within B Vitamins

It is important to remember that folate (B9) is one of eight essential B vitamins (B1, B2, B3, B5, B6, B7, B9, B12). These are organic compounds the body needs but generally cannot synthesize, primarily functioning as cofactors for enzymes. Deficiencies in most B vitamins have been associated with depressive symptoms. Clinical testing commonly focuses on folate and vitamin B12 (cobalamin) due to their higher prevalence of deficiency. Treatment for B12 deficiency often requires intramuscular injections due to potential gastrointestinal absorption issues and is frequently managed by primary care physicians.

Conclusion

Folate metabolism plays a significant role in the pathophysiology of depression. L-methylfolate, the biologically active form, stands out as an evidence-based, safe, and cost-effective augmentation strategy for antidepressant treatment, particularly at the recommended 15 mg/day dose. Its efficacy is comparable to standard pharmacologic augmenters, with evidence suggesting a potentially larger effect size in individuals with specific MTHFR polymorphisms. Furthermore, it avoids the significant side effect burden associated with agents like atypical antipsychotics. Clinical predictors such as obesity, inflammation, and the use of certain medications can help identify patients more likely to benefit, often obviating the need for routine MTHFR genetic testing. While SAMe shares metabolic pathways with L-methylfolate, the current evidence supporting its use specifically for depression is less robust, although it may offer benefits in certain comorbid conditions like osteoarthritis or fibromyalgia. Integrating L-methylfolate into treatment algorithms offers a targeted biological approach for managing depression.

References

This article is based on information presented in The Carlat Psychiatry Podcast plus further literature review around the trials for chronic pain.

Literature Review

Literature Review

Reviews from the last 7 years: review articles, free review articles, systematic reviews, meta-analyses, NCBI Bookshelf

Articles from all years: PubMed search, Google Scholar search.

TRIP Database: clinical publications about evidence-based medicine.

Other Wikis: Radiopaedia, Wikipedia Search, Wikipedia I Feel Lucky, Orthobullets,